09 Dec PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452
MALVERN, Pa. and SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage...
09 Dec SFJ Pharmaceuticals® partner, Apellis, enters Strategic Collaboration with Sobi to Develop and Commercialize Pegcetacoplan in Hematologic Indications outside the U.S.
PLEASANTON, Calif., Oct. 27, 2020 /PRNewswire/ — SFJ Pharmaceuticals® (“SFJ”) is pleased to note that its partner Apellis Pharmaceuticals Inc....
29 Oct SFJ Pharmaceuticals® partner, Apellis, enters Strategic Collaboration with Sobi to Develop and Commercialize Pegcetacoplan in Hematologic Indications outside the U.S.
PLEASANTON, Calif., Oct. 27, 2020 /PRNewswire/ -- SFJ Pharmaceuticals® ("SFJ") is pleased to note that its partner Apellis Pharmaceuticals Inc. ("Apellis") (Waltham, MA) and Swedish Orphan Biovitrum AB ("Sobi™") (Stockholm, Sweden) today announced a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for...
10 Jan PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452
PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452 PDF Version PhaseBio to receive up to $120 million in development funding PhaseBio retains exclusive worldwide commercial rights to PB2452 MALVERN, Pa. and SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization...
10 Jan Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2)
News Release Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) January 7, 2020 Pegcetacoplan met the primary endpoint in the PEGASUS study, demonstrating superiority to eculizumab (p<0.0001) with an improvement in adjusted means of 3.8...
07 Jan Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2)
WALTHAM, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company...
03 Apr VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU)
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO® (dacomitinib), a tyrosine kinase inhibitor (TKI), as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor...
28 Feb Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals®
Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains exclusive worldwide commercial rights to APL-2 in all indications WALTHAM Mass., and CRESTWOOD, Ky., February...
21 Nov Annuals of Oncology – 10-20-2018 – Axitinib
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial Background: The ATLAS trial compared axitinib versus placebo in patients with locoregional renal cell carcinoma (RCC) at risk of recurrence after nephrectomy. Patients and methods: In a phase...
25 Oct Eisai Launches Anticancer Agent Lenvima®
Eisai Launches Anticancer Agent Lenvima® (Lenvatinib Mesylate) In United Kingdom Indicated For Advanced Thyroid Cancer Refractory To Radioactive Iodine Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its U.K. subsidiary Eisai Europe Ltd. has launched its in-house developed novel anticancer agent Lenvima®...
- 1
- 2